The SGLT-2 inhibitors continue to garner headlines and scientific publications as our knowledge of how they work and what they can do increases. Part of the reason all this is happening at a rapid pace is the multiple brands available on the class. This means that endpoint studies can be going on that we don’t even know about and meta evaluations of these many studies often mean we will find another benefit from the class. This month we have a set of interviews with Dr. Jim McDermott, Vice President of US Medical Affairs for Diabetes at AstraZeneca.
He shares some of his insights in an exclusive 6-part interview that our publisher, Steve Freed, put together at the recent ADA Scientific Sessions.